Literature DB >> 26697203

Abdominal metastases from colorectal cancer: intraperitoneal therapy.

Hamza Guend1, Sunil Patel1, Garrett M Nash1.   

Abstract

Patients with peritoneal metastasis from colorectal cancer represent a distinct subset with regional disease rather than systemic disease. They often have poorer survival outcomes with systemic chemotherapy. Optimal cytoreductive surgery and intraperitoneal chemotherapy (IPC) offers such patients a more directed therapy with improved survival. In this review, we discuss the diagnosis, evaluation and classification, as well as rational for treatment of peritoneal carcinomatosis (PC) secondary to colorectal cancer.

Entities:  

Keywords:  Colorectal peritoneal carcinomatosis (PC); cytoreductive surgery; intraperitoneal chemotherapy (IPC)

Year:  2015        PMID： 26697203      PMCID： PMC4671857          DOI： 10.3978/j.issn.2078-6891.2015.078

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  39 in total

1.  Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.

Authors:  Jan Franko; Qian Shi; Charles D Goldman; Barbara A Pockaj; Garth D Nelson; Richard M Goldberg; Henry C Pitot; Axel Grothey; Steven R Alberts; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer.

Authors:  J Segelman; F Granath; T Holm; M Machado; H Mahteme; A Martling
Journal:  Br J Surg       Date:  2012-01-27       Impact factor: 6.939

Review 3.  Peritoneal debulking/intraperitoneal chemotherapy-non-sarcoma.

Authors:  Kaitlyn J Kelly; Garrett M Nash
Journal:  J Surg Oncol       Date:  2013-10-24       Impact factor: 3.454

4.  The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis.

Authors:  Jesus Esquivel; Andrew M Lowy; Maurie Markman; Terence Chua; Joerg Pelz; Dario Baratti; Joel M Baumgartner; Richard Berri; Pedro Bretcha-Boix; Marcello Deraco; Guillermo Flores-Ayala; Olivier Glehen; Alberto Gomez-Portilla; Santiago González-Moreno; Martin Goodman; Evgenia Halkia; Shigeki Kusamura; Mecker Moller; Guillaume Passot; Marc Pocard; George Salti; Armando Sardi; Maheswari Senthil; John Spilioitis; Juan Torres-Melero; Kiran Turaga; Richard Trout
Journal:  Ann Surg Oncol       Date:  2014-05-23       Impact factor: 5.344

Review 5.  Current treatment options for colon cancer peritoneal carcinomatosis.

Authors:  Tomoyoshi Aoyagi; Krista P Terracina; Ali Raza; Kazuaki Takabe
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

6.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

Authors:  D S Alberts; P Y Liu; E V Hannigan; R O'Toole; S D Williams; J A Young; E W Franklin; D L Clarke-Pearson; V K Malviya; B DuBeshter
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

7.  Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.

Authors:  R L Dedrick; C E Myers; P M Bungay; V T DeVita
Journal:  Cancer Treat Rep       Date:  1978-01

8.  Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer.

Authors:  S L Blair; D Z Chu; R E Schwarz
Journal:  Ann Surg Oncol       Date:  2001-09       Impact factor: 5.344

Review 9.  Peritoneal-plasma barrier.

Authors:  P Jacquet; P H Sugarbaker
Journal:  Cancer Treat Res       Date:  1996

10.  Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.

Authors:  Dominique Elias; Jérémie H Lefevre; Julie Chevalier; Antoine Brouquet; Frédéric Marchal; Jean-Marc Classe; Gwenaël Ferron; Jean-Marc Guilloit; Pierre Meeus; Diane Goéré; Julia Bonastre
Journal:  J Clin Oncol       Date:  2008-12-22       Impact factor: 44.544
View more
  4 in total

1.  Preoperative intraperitoneal oxaliplatin for unresectable peritoneal carcinomatosis of colorectal origin: a pilot study.

Authors:  Olivia Sgarbura; Emmanuelle Samalin; Sébastien Carrere; Thibault Mazard; Hélène de Forges; Mathias Alline; Marie-Hélène Pissas; Fabienne Portales; Marc Ychou; François Quenet
Journal:  Pleura Peritoneum       Date:  2016-12-21

2.  Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis.

Authors:  Wei Xia Ang; Zhendong Li; Zhixia Chi; Shou-Hui Du; Can Chen; Johan C K Tay; Han Chong Toh; John E Connolly; Xue Hu Xu; Shu Wang
Journal:  Oncotarget       Date:  2017-02-21

3.  Definition and Prediction of Early Recurrence and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: Towards Predicting Oncologic Futility Preoperatively.

Authors:  Caroline J Rieser; Heather Jones; Lauren B Hall; Eliza Kang; Shannon Altpeter; Amer H Zureikat; Matthew P Holtzman; Andrew Lee; Melanie Ongchin; James F Pingpank; M Haroon A Choudry; David L Bartlett
Journal:  Ann Surg Oncol       Date:  2021-07-05       Impact factor: 5.344

4.  Surgical treatment strategy for locally advanced colorectal cancer with abdominal wall invasion.

Authors:  Zhicheng Song; Dongchao Yang; Heng Song; Wenpei Dong; Jugang Wu; Jianjun Yang; Yan Gu
Journal:  Ann Transl Med       Date:  2021-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.